To hear about similar clinical trials, please enter your email below
Trial Title:
A Compassionate Use (CU) Program of Odronextamab
NCT ID:
NCT05619367
Condition:
Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Diffuse Large B-Cell Lymphoma (DLBCL)
B-Cell Non-Hodgkin Lymphoma (NHL)
High-Grade B-Cell Lymphoma (HGBCL)
Conditions: Official terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Study type:
Expanded Access
Overall status:
Available
Intervention:
Intervention type:
Drug
Intervention name:
Odronextamab
Other name:
REGN1979
Summary:
Provide compassionate use of odronextamab
Criteria for eligibility:
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Lead sponsor:
Agency:
Regeneron Pharmaceuticals
Agency class:
Industry
Source:
Regeneron Pharmaceuticals
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05619367
